New chemo schedule hopes to outsmart aggressive brain tumors in seniors
NCT ID NCT07476794
First seen Apr 02, 2026 · Last updated Jun 20, 2026 · Updated 13 times
Summary
This study tests a different way of giving the chemotherapy drug temozolomide to elderly patients (65+) with a tough-to-treat type of brain cancer called glioblastoma. The tumor has a marker (unmethylated MGMT) that usually makes standard chemo less effective. Researchers hope that giving the drug daily for 5 days every 28 days, instead of the usual schedule, will help slow the cancer and improve survival. The trial involves 118 participants who have already completed radiation with standard temozolomide.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sunnybrook Health Sciences Centre
RECRUITINGToronto, Ontario, M4N3M5, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
temozolomide
What this could lead to
If successful, this modified dosing schedule could offer a better way to slow tumor growth and extend survival for elderly glioblastoma patients whose tumors are resistant to standard chemotherapy.
What could go wrong
This is a Phase 2 trial with only 118 participants, so results are preliminary. The modified regimen may not improve outcomes and could cause side effects like fatigue or low blood counts.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.